Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Chronic Lymphocytic Leukemia in a Beta Thalassemia Major Adult Female “Rare Combination": A Case Report

CLL - 395

Chronic Lymphocytic Leukemia in a Beta Thalassemia Major Adult Female “Rare Combination": A Case Report

Fatima Alqassab

Poster Presenter: Fatima Alqassab

Thumbnail for Diagnostic Accuracy of Noncoding RNAs in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

CLL - 419

Diagnostic Accuracy of Noncoding RNAs in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Jasvindar Kumar

Poster Presenter: Jasvindar Kumar

Previous 1...52 53 54 55 56 57 58...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

$Thumbnail for Comparative Efficacy of Zanubrutinib in Relapsed/Refractory CLL: Prolonged Progression-Free Survival From a Population-Adjusted Indirect Comparison Using Multilevel Network Meta-Regression$

CLL - 420

Comparative Efficacy of Zanubrutinib in Relapsed/Refractory CLL: Prolonged Progression-Free Survival From a Population-Adjusted Indirect Comparison Using Multilevel Network Meta-Regression

Jasvindar Kumar

Poster Presenter: Jasvindar Kumar

Thumbnail for Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

CLL - 427

Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

Zulfa Omer

Poster Presenter: Zulfa Omer

Thumbnail for Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

CLL - 429

Daybreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton Tyrosine Kinase (BTK) Degrader, in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Treated With a Covalent BTK Inhibitor, a Noncovalent BTK Inhibitor, and a BCL2 Inhibitor

Michael Tees

Poster Presenter: Michael Tees

$Thumbnail for DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma$

CLL - 432

DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton Tyrosine Kinase Degrader Bexobrutideg (NX-5948) vs Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Megan Wang

Poster Presenter: Megan Wang

Thumbnail for Efficacy and Safety of Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis

CLL - 437

Efficacy and Safety of Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis

Madho Mal

Poster Presenter: Madho Mal

Thumbnail for The Impact of Baseline Immune-Inflammatory Indices and Microenvironment in Richter Transformation: A Case Series

CLL - 444

The Impact of Baseline Immune-Inflammatory Indices and Microenvironment in Richter Transformation: A Case Series

Maria D'Amato

Poster Presenter: Maria D'Amato

Thumbnail for Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated With Rituximab-Venetoclax in Real World: Insights From the “Dedalus" Protocol

CLL - 446

Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated With Rituximab-Venetoclax in Real World: Insights From the “Dedalus" Protocol

Maria D'Amato

Poster Presenter: Maria D'Amato

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors